4D Molecular Therapeutics Inc
FDMT5.280USD
-1.140-17.76%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
244.60MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über 4D Molecular Therapeutics Inc Unternehmen
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
Unternehmensinformationen
BörsenkürzelFDMT
Name des Unternehmens4D Molecular Therapeutics Inc
IPO-datumDec 11, 2020
CEODr. David Kirn, M.D.
Anzahl der mitarbeiter227
WertpapierartOrdinary Share
GeschäftsjahresendeDec 11
Addresse5858 Horton Street #455
StadtEMERYVILLE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94608
Telefon15105052680
Websitehttps://4dmoleculartherapeutics.com/
BörsenkürzelFDMT
IPO-datumDec 11, 2020
CEODr. David Kirn, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.66M
-0.02%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Dr. Scott Bizily, J.D., Ph.D.
Dr. Scott Bizily, J.D., Ph.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Dhaval Desai, Pharm.D.
Dr. Dhaval Desai, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Charles P. Theuer, M.D., Ph.D.
Dr. Charles P. Theuer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Nancy Miller-Rich
Ms. Nancy Miller-Rich
Independent Director
Independent Director
--
--
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Simms
Mr. Christopher (Chris) Simms
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Robert (Bob) Kim, M.D.
Dr. Robert (Bob) Kim, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.66M
-0.02%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Dr. Scott Bizily, J.D., Ph.D.
Dr. Scott Bizily, J.D., Ph.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Dhaval Desai, Pharm.D.
Dr. Dhaval Desai, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Charles P. Theuer, M.D., Ph.D.
Dr. Charles P. Theuer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
14.00K
0.00%
Netherlands
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
9.85%
BVF Partners L.P.
9.85%
Goldman Sachs & Company, Inc.
8.09%
BlackRock Institutional Trust Company, N.A.
7.63%
The Vanguard Group, Inc.
5.95%
Other
58.64%
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
9.85%
BVF Partners L.P.
9.85%
Goldman Sachs & Company, Inc.
8.09%
BlackRock Institutional Trust Company, N.A.
7.63%
The Vanguard Group, Inc.
5.95%
Other
58.64%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
23.29%
Investment Advisor
21.67%
Hedge Fund
17.81%
Venture Capital
16.25%
Research Firm
14.94%
Individual Investor
3.88%
Sovereign Wealth Fund
1.08%
Pension Fund
1.01%
Bank and Trust
0.10%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
351
46.53M
100.45%
-12.51M
2025Q1
358
46.38M
99.71%
-13.16M
2024Q4
357
49.60M
107.13%
-13.93M
2024Q3
350
60.77M
117.85%
-4.39M
2024Q2
340
60.30M
117.01%
-2.54M
2024Q1
324
59.47M
116.84%
+10.27M
2023Q4
284
45.54M
106.82%
-1.53M
2023Q3
275
45.63M
108.12%
-4.94M
2023Q2
263
44.82M
109.79%
-393.70K
2023Q1
254
34.42M
103.72%
-2.13M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
RA Capital Management, LP
4.56M
9.85%
--
--
Mar 31, 2025
BVF Partners L.P.
4.56M
9.85%
+1.89M
+70.79%
Mar 31, 2025
Goldman Sachs & Company, Inc.
3.75M
8.09%
-81.59K
-2.13%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.53M
7.63%
-321.37K
-8.34%
Mar 31, 2025
The Vanguard Group, Inc.
2.76M
5.95%
-97.19K
-3.40%
Mar 31, 2025
Novo Holdings A/S
1.95M
4.21%
+450.00K
+30.00%
Mar 31, 2025
Janus Henderson Investors
1.89M
4.08%
-360.31K
-16.00%
Mar 31, 2025
Kirn (David)
1.66M
3.58%
-360.00
-0.02%
Apr 24, 2025
Millennium Management LLC
1.63M
3.53%
+213.26K
+15.01%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.29M
2.78%
-316.21K
-19.71%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Federated Hermes MDT Small Cap Core ETF
0.32%
Harbor Human Capital Factor US Small Cap ETF
0.08%
iShares Micro-Cap ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.02%
iShares Health Innovation Active ETF
0.02%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
Mehr Anzeigen
Federated Hermes MDT Small Cap Core ETF
Anteil0.32%
Harbor Human Capital Factor US Small Cap ETF
Anteil0.08%
iShares Micro-Cap ETF
Anteil0.03%
ProShares Ultra Nasdaq Biotechnology
Anteil0.02%
Invesco Nasdaq Biotechnology ETF
Anteil0.02%
iShares Biotechnology ETF
Anteil0.02%
iShares Health Innovation Active ETF
Anteil0.02%
ProShares Hedge Replication ETF
Anteil0.01%
iShares Russell 2000 Value ETF
Anteil0.01%
Avantis US Small Cap Equity ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
